New Akums Patent Offers Safer Medication Delivery for Expectant Mothers

A leading contract research and manufacturing organization, Akums Drugs & Pharmaceuticals, has established a patent for its novel extended-release invention of doxylamine and pyridoxine. Over 80 percent of expectant mothers face the condition of nausea and vomiting during their pregnancy and this innovative patent will reduce this particular issue.  

While most women find relief by the 16th week, a major percentage continues facing symptoms during pregnancy, impacting daily life. Akums’ patented "tablet-in-tablet" design directly addresses this issue. The outer layer delivers rapid symptom relief, while the inner core ensures continued relief and reduces the need for frequent dosing and improves patient observance.

This dual-action delivery system blends immediate and extended-release mechanisms within a single tablet, improving therapeutic results and providing steady symptom control. For pregnant women, where safety and minimalism are vital, this approach brings a welcome advancement in maternal care.

Authorized by bioequivalence studies and approved by the Drug Controller General of India (DCGI), the formulation meets high criteria of safety and efficacy. While patient study numbers remain anonymous, regulatory approval underscores its potential in improving pregnancy-related nausea management.

Sanjeev Jain, Managing Director of Akums, highlighted, “True innovation stems from empathy. With this formulation, we’re supporting women through a critical phase of life, ensuring better access to effective, reliable care.”

Akums continues to lead in pharmaceutical innovation, with over 4,100 commercialized formulations and 220+ new products in development. The company is influential in drug delivery systems globally, with a strong existence in both domestic and international markets.